Next Generation Antibody Therapeutics

The ambition of the next generation antibody therapeutics program is to develop next generation monoclonal antibodies and scaffold binders to targets of pharmaceutical interest.

The program involves development of small affinity proteins, in particular affibody molecules, that will be explored in bi- tri- or multispecific formats. Also bivalent binders, comprising modules binding to separate adjacent epitopes on the target protein (i.e. bi-paratopic), are investigated. This modular architecture of fusion proteins allows for design of constructs that combines an efficient localization to a certain target protein or cell type, combined with an effector module and/or a moiety for in vivo half-life extension to adjust the pharmacokinetic properties.

Program Management

Belongs to: WCPR
Last changed: Mar 27, 2017